8-K: Definitive Healthcare Exceeds Q4 Guidance Amid Revenue Decline

Definitive Healthcare Corp. announced fourth quarter and full year 2025 financial results, with Q4 revenue exceeding guidance despite a year-over-year decrease.

Summary

• Fourth quarter 2025 revenue was $61.5 million, a 1% decrease from $62.3 million in Q4 2024.
• Full year 2025 revenue was $241.5 million, compared to $252.2 million for the full year 2024.
• Net Loss for Q4 2025 was $(17.1) million, inclusive of $19.5 million in goodwill impairment charges, a significant improvement from $(84.7) million in Q4 2024.
• Full year 2025 Net Loss was $(199.3) million, inclusive of $196.1 million in goodwill impairment charges, compared to $(591.4) million in 2024.
• Adjusted EBITDA for Q4 2025 was $18.0 million (29% of revenue), up from $17.5 million (28% of revenue) in Q4 2024.
• Full year 2025 Adjusted EBITDA was $70.4 million (29% of revenue), down from $79.1 million (31% of revenue) in 2024.
• Cash Flow from Operations was $2.7 million in Q4 2025 and $53.8 million for the full year 2025.
• Unlevered Free Cash Flow was $2.5 million in Q4 2025 and $54.9 million for the full year 2025.
• Fourth quarter results were at or above the high end of guidance ranges for both revenue and Adjusted EBITDA.
• The company is focused on improving retention rates and increasing upsell and cross-sell activity in 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While Q4 results surpassed guidance, the underlying trends of declining revenue, significant goodwill impairment, and a negative outlook for 2026 suggest ongoing challenges for the company.

Positives

• Fourth quarter 2025 revenue of $61.5 million exceeded the company's guidance.
• Fourth quarter 2025 Adjusted EBITDA of $18.0 million was at or above the high end of the company's guidance ranges.
• Net Loss significantly improved in Q4 2025 to $(17.1) million from $(84.7) million in Q4 2024, despite goodwill impairment charges.
• Full year Net Loss also improved to $(199.3) million from $(591.4) million in 2024.
• Adjusted EBITDA margin improved in Q4 2025 to 29% from 28% in Q4 2024.
• Secured new customer logos and expansion opportunities across all end-markets in Q4 2025.
• A proactive customer success approach converted a forecasted churn into a successful multi-year renewal for a regional health system.

Negatives

• Revenue decreased by 1% in Q4 2025 compared to Q4 2024.
• Full year 2025 revenue decreased to $241.5 million from $252.2 million in 2024.
• Significant goodwill impairment charges were recorded: $19.5 million in Q4 2025 and $196.1 million for the full year 2025.
• Adjusted Net Income decreased in Q4 2025 to $8.6 million from $12.6 million in Q4 2024.
• Full year 2025 Adjusted Net Income decreased to $34.9 million from $55.1 million in 2024.
• Full year 2025 Adjusted EBITDA decreased to $70.4 million from $79.1 million in 2024, with the margin declining to 29% from 31%.
• First Quarter 2026 and Full Year 2026 revenue guidance indicates further year-over-year declines.

Risks

• Global geopolitical tension and difficult macroeconomic conditions.
• Actual or potential changes in international, national, regional, and local economic, business, and financial conditions, including tariffs, sanctions, trade barriers, recessions, fluctuating inflation, high interest rates, volatility in the capital markets, and related market uncertainty.
• Inability to acquire new customers and generate additional revenue from existing customers.
• Inability to generate sales of subscriptions to the platform or any decline in demand for the platform and the data offered.
• The competitiveness of the market in which the company operates and its ability to compete effectively.
• Failure to maintain and improve the platform, or develop new modules or insights for healthcare commercial intelligence.
• Inability to obtain and maintain accurate, comprehensive, or reliable data, which could result in reduced demand for the platform.
• Loss of access to data providers.
• Failure to respond to advances in healthcare commercial intelligence.
• Inability to attract new customers and expand subscriptions of current customers.
• The ability to successfully transition executive leadership.
• The possibility that security measures are breached or unauthorized access to data is otherwise obtained.

Future Outlook

The company projects Q1 2026 revenue between $54.0 million and $56.0 million, with Adjusted EBITDA in the range of $12.0 million to $13.0 million. For the full year 2026, revenue is expected to be between $220.0 million and $226.0 million, and Adjusted EBITDA between $53.0 million and $58.0 million. This guidance indicates a continued decline in revenue and Adjusted EBITDA compared to 2025 results.

Management Comments

• "Our fourth quarter results were at or above the high end of our guidance ranges on both the top and bottom line, demonstrating the meaningful progress we have made across our strategic pillars throughout 2025."
• "As we enter 2026, we are focused on continuing to improve retention rates and increase our upsell and cross-sell activity."
• "We remain confident that we are taking the right steps to deliver improved operational and financial performance over time."

Industry Context

StockSavvy.ai notes that Definitive Healthcare operates in the competitive healthcare market data and analytics sector, which is experiencing increasing demand for actionable insights. The company's focus on data quality, seamless integration, and proactive customer success aligns with broader industry trends emphasizing value-driven solutions and customer retention in a challenging economic environment. The reported revenue decline, however, suggests that even industry leaders are not immune to market pressures or internal operational challenges.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. Therefore, a direct comparison to industry standards with specific examples is not possible based solely on this document.

Stakeholder Impact

• Shareholders: Potential for continued stock price volatility due to declining revenue, significant goodwill impairment, and a negative outlook for 2026, despite exceeding Q4 guidance.
• Employees: No direct impact mentioned, but strategic initiatives and restructuring expenses (mentioned in non-GAAP adjustments) could imply past or future workforce adjustments.
• Customers: Continued focus on customer success, data quality, and integration aims to enhance value, potentially leading to better retention and expansion opportunities.
• Creditors: The company has term loan liabilities, and declining revenue and profitability could impact future debt servicing capacity, though current cash flow from operations is positive.

Next Steps

• Host a conference call on February 26, 2026, at 5:00 p.m. (Eastern Standard Time) to discuss financial results and business outlook.
• Continue efforts to improve retention rates and increase upsell and cross-sell activity in 2026.
• File Annual Report on Form 10-K for the fiscal year ended December 31, 2025, following this earnings release.

Key Dates

Recommendation

While Definitive Healthcare exceeded its Q4 guidance, the overall financial picture presented in the filing is concerning, with year-over-year revenue declines for both Q4 and the full year 2025, significant goodwill impairment charges, and a projected further decline in revenue and Adjusted EBITDA for 2026. The company's focus on improving retention and upsell/cross-sell is positive, but the current trends suggest a "hold" recommendation as investors await clearer signs of a turnaround and sustained growth. The stock may experience volatility due to the mixed signals.

Keywords

Healthcare data, Healthcare analytics, Financial results, Earnings report, Definitive Healthcare, DH, Q4 2025, Full Year 2025, Financial guidance, Goodwill impairment, Adjusted EBITDA, Revenue, Net loss, Commercial intelligence